Management of Breast Symptoms: National Guideline for Primary Care Doctors & Family Physicians

Objectives

Improve breast cancer outcomes in Sri Lanka through breast awareness, risk assessment, early detection, accurate diagnosis, multidisciplinary treatment, survivorship follow-up and hereditary cancer services. Breast cancer is identified as the commonest cancer among Sri Lankan women, representing approximately 27% of female cancers, while an estimated 5–10% of cases have a strong hereditary component and a further 15–25% are familial.[1][2]

• Promote modifiable risk reduction through healthy weight, physical activity, reduced alcohol consumption and avoidance of smoking, while recognising reproductive, hormonal, environmental, clinical and inherited risk factors.[1][3][4]
• Enhance early presentation by encouraging women to know their normal breasts, report changes promptly and understand that abnormalities require clinical confirmation rather than necessarily indicating cancer.[5][6]
• Provide monthly breast self-examination from age 20, clinical breast examination every three years for women aged 20–40 and annually from age 40, with earlier annual examination for women with relevant early-onset family histories.[7][8]
• Offer screening mammography every two to three years to women aged 50–69 who request it, subject to adequate national mammography capacity, and apply intensified surveillance for women with defined high-risk characteristics.[7]
• Use clinical assessment, imaging and pathology to diagnose and stage breast cancer, then provide stage-appropriate surgery, radiotherapy and systemic treatment according to tumour features and patient suitability.[8][9][10][11]
• Support breast-conserving treatment where feasible, while ensuring access to mastectomy, reconstruction, axillary staging, lymphoedema management and risk-reducing interventions where clinically appropriate.[10][12]
• Identify hereditary cancer risk through family and personal history, genetic counselling and testing, and use results to inform surveillance, treatment, risk reduction and reproductive decision-making.[13][14][15]

Implementation

Delivery spans primary care, surgical and specialist breast services, tertiary multidisciplinary cancer care, and genetic services. The approach combines sensitive communication, structured clinical assessment, referral, diagnostic triple assessment, pathology-led treatment planning and risk-stratified follow-up; it does not set out a formal programme governance structure, budget or system-wide accountability framework.[5][10][16][17][18]

• Assess women presenting with lumps, asymmetrical thickening, skin or nipple changes, unilateral non-cyclical pain, spontaneous single-duct discharge or axillary masses, and refer concerning symptoms to a surgical unit, surgical clinic or breast clinic, including when a reported lump is not palpable.[4][5]
• Conduct clinical breast examination in a private, well-lit setting, explain the procedure, use a female chaperone where a male clinician examines the patient, inspect and palpate the full breast area systematically, and examine nodal areas and nipple discharge.[19][7]
• Establish specialist breast clinics where available, led by a consultant surgeon or consultant oncosurgeon and supported by trained medical and nursing staff with timely radiological and pathological assessment.[5]
• Apply triple assessment comprising clinical history and examination, mammography or ultrasonography, and cytology or non-excision core biopsy where available; refer to a specialist centre if any component is indeterminate, suspicious or malignant.[5]
• Use bilateral mammography, ultrasound and pathological examination for suspected cancer, obtain a core needle biopsy before surgery where possible, and use World Health Organization classification and tumour-node-metastasis staging for final pathological diagnosis.[8][9]
• Plan treatment through a multidisciplinary team including a breast surgeon, radiologist, pathologist, medical oncologist and radiation oncologist. Use tumour stage, nodal status, histological grade, surgical margins, and oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status to guide management.[10][11]
• Provide primary systemic therapy for locally advanced or inflammatory cancer and selected large operable tumours; complete biopsy, biomarker assessment and clinical staging before treatment.[16]
• Schedule follow-up examinations every three to six months in the first three years, every six to twelve months in years four and five, and annually thereafter, with annual mammography after the specified post-conservation treatment baseline. Avoid routine imaging and laboratory investigations in asymptomatic patients without clinical indications.[16]
• Develop a three-generation pedigree on maternal and paternal sides, verify reported diagnoses where possible, and refer qualifying individuals for genetic counselling and testing. The Human Genetics Unit, Faculty of Medicine, University of Colombo, is identified as a referral service for genetic consultation.[13][20]
• Provide pre-test and post-test counselling, informed consent, interpretation of results, discussion of privacy and psychological implications, and targeted family testing where a pathogenic mutation is identified.[14][15]
• Apply recommendations with individual clinical data, available diagnostic and treatment options, and professional judgement, recognising that alternative acceptable methods may achieve similar outcomes and that practice may evolve.[18]

Monitoring & Evaluation

Monitoring is principally clinical rather than programme-based. The material sets service-delivery benchmarks for breast awareness, clinical examination, screening, diagnostic assessment, staging and post-treatment follow-up, but does not establish a formal national monitoring, reporting, surveillance or accountability framework.[5][6][19][7][8][9][10][12][11][16][2][13][14][15][21][20]

• Record presenting symptoms, previous breast conditions and investigations, biopsy findings, and relevant personal and familial risk factors to support further investigation and care.[6]
• Apply triple assessment, comprising clinical history and examination, imaging, and non-excision biopsy or cytology, because combined assessment is more sensitive than any single component. Treat any indeterminate, suspicious or malignant component as a positive result requiring specialist-centre follow-up.[5]
• Use breast screening in women without signs or symptoms, with the type and timing of assessment determined by individual risk.[6]
• Apply operational screening intervals by promoting monthly breast self-examination from age 20, providing clinical breast examination every three years for women aged 20 to 40 and annually from age 40, and offering mammography every two to three years to women aged 50 to 69 who request it where facilities are adequate.[7]
• Document diagnostic and staging findings through clinical, radiological and pathological assessment, including bilateral mammography and ultrasound where indicated, core biopsy where possible, World Health Organization tumour classification, and tumour-node-metastases staging.[8][9]
• Record postoperative pathological tumour, node and metastasis findings, including tumour characteristics, lymph-node totals and involvement, resection margins, vascular or lymphovascular invasion, and oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression.[10]
• Assess treatment suitability and outcomes using tumour stage, nodal status, margin clearance, receptor status, residual disease after neoadjuvant treatment and lymphoedema.[10][12]
• Schedule clinical follow-up every three to six months during the first three years, every six to twelve months in years four and five, and annually thereafter.[16]
• Undertake post-treatment mammography after breast-conserving surgery one year after the initial mammogram and at least six months after radiotherapy, using the later date, then continue annual mammography unless otherwise indicated.[16]
• Avoid routine blood tests, imaging and tumour-marker testing in asymptomatic patients without specific clinical findings.[16]
• Use age-based clinical examinations and imaging schedules as surveillance measures for people at increased hereditary cancer risk, including mutation carriers and others meeting genetic-risk criteria.[15][21]

Costing & Financing

No explicit budgets, allocations, financing sources, resource-mobilisation arrangements, funding gaps or quantified economic assumptions are provided for breast cancer screening, diagnosis, treatment, follow-up, hereditary-risk management or genetic services.[5][6][19][7][8][9][10][12][11][16][22][2][13][14][15][21][20]

• Recognise mammography as resource-intensive because it requires elaborate equipment and highly trained personnel.[7]
• Recognise breast magnetic resonance imaging as more costly and not readily available, limiting its routine use and supporting its use principally for women at high risk or for defined diagnostic challenges.[7][9]
• Condition mammography screening for women aged 50 to 69 on the availability of adequate mammography facilities throughout the country.[7]
• Provide specialised breast-clinic services where available, led by a consultant surgeon or consultant oncosurgeon and supported by trained medical and nursing staff with timely radiological and pathological assessment. The source identifies this service capacity but does not cost it.[5]
• Provide multidisciplinary treatment planning involving breast surgery, radiology, pathology, medical oncology and radiation oncology. The source does not specify the financing or workforce costs associated with this model.[10]
• Make lymphoedema management dependent on trained therapists, compression bandaging, manual lymphatic drainage and graduated compression garments, without specifying their cost or funding source.[10]
• Describe multi-gene cancer-panel testing as a rapid and economical alternative to single-gene testing, because it can analyse multiple genes simultaneously and may save patients money and time when multiple hereditary cancer syndromes are suspected.[15]
• Note that a Sri Lankan next-generation sequencing panel examines 94 genes associated with common and rare cancers, but no test price, subsidy, reimbursement mechanism or programme budget is specified.[15]
• Refer patients for genetic consultation to the Human Genetics Unit, Faculty of Medicine, University of Colombo, while leaving the funding and affordability of consultation, testing, surveillance and risk-reducing interventions unspecified.[21][20]